

# Rowan T Chlebowski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4412699/publications.pdf>

Version: 2024-02-01

377  
papers

38,736  
citations

5261

83  
h-index

3031

188  
g-index

381  
all docs

381  
docs citations

381  
times ranked

27535  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Coalaâ€Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment. <i>Cancer</i> , 2022, 128, 160-168.	2.0	27
2	Cardiometabolic risk factors, physical activity, and postmenopausal breast cancer mortality: results from the Womenâ€™s Health Initiative. <i>BMC Women's Health</i> , 2022, 22, 32.	0.8	4
3	Reply to the siren's song of anonymous webâ€based sampling. <i>Cancer</i> , 2022, 128, 1873-1874.	2.0	0
4	Breast Cancer Prevention and Breast Cancer Mortality. <i>JCO Oncology Practice</i> , 2022, 18, 522-523.	1.4	4
5	Menopausal Hormone Therapy and Breast Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2022, 28, 169-175.	1.0	4
6	Long-term dietary intervention influence on physical activity in the Womenâ€™s Health Initiative Dietary Modification randomized trial. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 43-54.	1.1	1
7	Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative. <i>Cancer</i> , 2021, 127, 598-608.	2.0	31
8	Reply to The Women's Health Initiative; hormone replacement therapy; and Surveillance, Epidemiology, and End Results data and The importance of comprehensive data and statistical testing in the interpretation of breast cancer incidence trends. <i>Cancer</i> , 2021, 127, 813-814.	2.0	1
9	Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50â€59 Years of Age. <i>American Journal of Epidemiology</i> , 2021, 190, 365-375.	1.6	27
10	Reply to WC Willett and D Ludwig. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 2120-2122.	2.2	0
11	Metabolic syndrome risk components and mortality after tripleâ€negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative. <i>Cancer</i> , 2021, 127, 1658-1667.	2.0	2
12	Nutritional epidemiology and the Womenâ€™s Health Initiative: a review. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1083-1092.	2.2	14
13	Low-fat dietary pattern and breast cancer mortality by metabolic syndrome components: a secondary analysis of the Womenâ€™s Health Initiative (WHI) randomised trial. <i>British Journal of Cancer</i> , 2021, 125, 372-379.	2.9	10
14	Low-Fat Dietary Modification and Risk of Ductal Carcinoma In Situ of the Breast in the Women's Health Initiative Dietary Modification Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1753-1756.	1.1	2
15	A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab072.	1.4	12
16	Breast Cancer Prevention: Time for Change. <i>JCO Oncology Practice</i> , 2021, 17, 709-716.	1.4	20
17	Abstract 789: Benign breast disease and all-cause and breast cancer-specific mortality among postmenopausal women in the Women's Health Initiative. , 2021, , .		0
18	Performance of the IBIS/Tylerâ€Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. <i>Cancer</i> , 2021, 127, 3742-3750.	2.0	21

#	ARTICLE	IF	CITATIONS
19	Sleep medication use and risk of fractures in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 541-548.	1.1	1
20	Insulin Resistance and Cancer-Specific and All-Cause Mortality in Postmenopausal Women: The Women's Health Initiative. <i>Journal of the National Cancer Institute</i> , 2020, 112, 170-178.	3.0	34
21	The association between DXA-derived body fat measures and breast cancer risk among postmenopausal women in the Women's Health Initiative. <i>Cancer Medicine</i> , 2020, 9, 1581-1599.	1.3	8
22	Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?. <i>Breast Journal</i> , 2020, 26, 2199-2202.	0.4	3
23	Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers. <i>JAMA Network Open</i> , 2020, 3, e207227.	2.8	22
24	Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 369.	3.8	210
25	Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival. <i>Annals of Surgical Oncology</i> , 2020, 27, 4687-4694.	0.7	21
26	Risk of Breast Cancer Associated with Estrogen DNA Adduct Biomarker. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2096-2099.	1.1	1
27	Prentice et al. Respond to "Studying Co-Occurrence of Multiple Outcomes". <i>American Journal of Epidemiology</i> , 2020, 189, 985-986.	1.6	0
28	Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative. <i>Oncologist</i> , 2020, 25, 712-721.	1.9	2
29	Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women's Health Initiative. <i>Cancer</i> , 2020, 126, 3638-3647.	2.0	48
30	Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women. <i>Cancer</i> , 2020, 126, 2956-2964.	2.0	17
31	Association of Diet Quality and Physical Activity on Obesity-Related Cancer Risk and Mortality in Black Women: Results from the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 591-598.	1.1	6
32	Dietary Moderation and Deaths From Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3071-3072.	0.8	5
33	Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1419-1428.	0.8	87
34	Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 767-775.	1.1	2
35	The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 747-757.	1.1	16
36	Low-fat dietary pattern and global cognitive function: Exploratory analyses of the Women's Health Initiative (WHI) randomized Dietary Modification trial. <i>EClinicalMedicine</i> , 2020, 18, 100240.	3.2	6

#	ARTICLE	IF	CITATIONS
37	Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials. <i>American Journal of Epidemiology</i> , 2020, 189, 972-981.	1.6	7
38	Genetic Predictors of Circulating 25-Hydroxyvitamin D and Prognosis after Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1128-1134.	1.1	1
39	Online Health Information "Seeking Among Older Women With Chronic Illness: Analysis of the Women's Health Initiative. <i>Journal of Medical Internet Research</i> , 2020, 22, e15906.	2.1	43
40	Postmenopausal Breast Cancer and Physical Function Change: A Difference-in-Differences Analysis. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1029-1036.	1.3	8
41	Protein Intake by Source and Breast Cancer Incidence and Mortality: The Women's Health Initiative. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa101.	1.4	6
42	Association of Normal-Weight Central Obesity With All-Cause and Cause-Specific Mortality Among Postmenopausal Women. <i>JAMA Network Open</i> , 2019, 2, e197337.	2.8	107
43	Intentional Weight Loss and Obesity-Related Cancer Risk. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz054.	1.4	80
44	Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 785-794.	1.1	50
45	Reply to F. Conforti et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 1840-1841.	0.8	0
46	Low-Fat Dietary Pattern among Postmenopausal Women Influences Long-Term Cancer, Cardiovascular Disease, and Diabetes Outcomes. <i>Journal of Nutrition</i> , 2019, 149, 1565-1574.	1.3	39
47	Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 858-861.	0.8	7
48	Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy. <i>Annals of Internal Medicine</i> , 2019, 171, 406.	2.0	40
49	Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative. <i>Menopause</i> , 2019, 26, 578-587.	0.8	12
50	Physical activity and weight gain after smoking cessation in postmenopausal women. <i>Menopause</i> , 2019, 26, 16-23.	0.8	5
51	Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?. <i>International Journal of Cancer</i> , 2019, 144, 730-740.	2.3	8
52	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	2.6	711
53	Adiposity, history of diabetes, and risk of pancreatic cancer in postmenopausal women. <i>Annals of Epidemiology</i> , 2019, 29, 23-29.e1.	0.9	6
54	Racial and Ethnic Differences in Anthropometric Measures as Risk Factors for Diabetes. <i>Diabetes Care</i> , 2019, 42, 126-133.	4.3	33

#	ARTICLE	IF	CITATIONS
55	Interaction of body mass index or waist-to-hip ratio and sun exposure associated with nonmelanoma skin cancer: A prospective study from the Women's Health Initiative. <i>Cancer</i> , 2019, 125, 1133-1142.	2.0	6
56	Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index. <i>JAMA Oncology</i> , 2019, 5, 155.	3.4	145
57	Weight loss and breast cancer incidence in postmenopausal women. <i>Cancer</i> , 2019, 125, 205-212.	2.0	66
58	Low-fat dietary pattern and breast cancer mortality by metabolic syndrome degree: Secondary analyses of the Women's Health Initiative (WHI) Dietary Modification randomized trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1539-1539.	0.8	1
59	Weight loss, diet composition and breast cancer incidence and outcome in postmenopausal women. <i>Oncotarget</i> , 2019, 10, 3088-3092.	0.8	9
60	Serum glucose and insulin and risk of cancers of the breast, endometrium, and ovary in postmenopausal women. <i>European Journal of Cancer Prevention</i> , 2018, 27, 261-268.	0.6	31
61	Postmenopausal Fracture History and Survival After Reproductive Cancer Diagnosis. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky001.	1.4	1
62	Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative. <i>Cancer</i> , 2018, 124, 1798-1807.	2.0	33
63	36-Item Short Form Survey (SF-36) Versus Gait Speed As Predictor of Preclinical Mobility Disability in Older Women: The Women's Health Initiative. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 706-713.	1.3	13
64	Post-Stroke Cancer Risk among Postmenopausal Women: The Women's Health Initiative. <i>Women's Health Issues</i> , 2018, 28, 29-34.	0.9	3
65	Breast cancer survivorship: state of the science. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 593-600.	1.1	9
66	Impact of hormone therapy on Medicare spending in the Women's Health Initiative randomized clinical trials. <i>American Heart Journal</i> , 2018, 198, 108-114.	1.2	3
67	Emerging combination endocrine therapies for advanced breast cancer. <i>Breast Journal</i> , 2018, 24, 214-215.	0.4	0
68	Association of Cataract Surgery With Mortality in Older Women. <i>JAMA Ophthalmology</i> , 2018, 136, 3.	1.4	27
69	Low-fat Dietary Pattern and Pancreatic Cancer Risk in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 49-56.	3.0	43
70	Serum lipids and risk of obesity-related cancers in postmenopausal women. <i>Cancer Causes and Control</i> , 2018, 29, 13-24.	0.8	27
71	Complexity of intermittent letrozole adjuvant therapy. <i>Lancet Oncology</i> , The, 2018, 19, 13-15.	5.1	0
72	Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. <i>Menopause</i> , 2018, 25, 11-20.	0.8	164

#	ARTICLE	IF	CITATIONS
73	Association between Dietary Energy Density and Obesity-Associated Cancer: Results from the Women's Health Initiative. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2018, 118, 617-626.	0.4	19
74	Low-Fat Dietary Pattern and Cancer Mortality in the Women's Health Initiative (WHI) Randomized Controlled Trial. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky065.	1.4	14
75	Breast Cancer Outcomes in a Racially and Ethnically Diverse Cohort of Insured Women. <i>Ethnicity and Disease</i> , 2018, 28, 565-574.	1.0	7
76	Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative. <i>PLoS ONE</i> , 2018, 13, e0207509.	1.1	13
77	Notice of Retraction and Replacement. Tseng et al. Association of cataract surgery with mortality in older women: findings from the Women's Health Initiative. <i>JAMA Ophthalmol.</i> 2018;136(1):3-10. <i>JAMA Ophthalmology</i> , 2018, 136, 1313.	1.4	2
78	Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival. <i>JAMA Oncology</i> , 2018, 4, e181212.	3.4	62
79	Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study. <i>Menopause</i> , 2018, 25, 985-991.	0.8	14
80	Stratified Probabilistic Bias Analysis for Body Mass Index-related Exposure Misclassification in Postmenopausal Women. <i>Epidemiology</i> , 2018, 29, 604-613.	1.2	19
81	Association of 25-hydroxyvitamin D levels and cutaneous melanoma: A nested case-control study of the Women's Health Initiative Observation Study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 145-147.	0.6	7
82	Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative (WHI).. <i>Journal of Clinical Oncology</i> , 2018, 36, e13567-e13567.	0.8	3
83	Trajectory of recurrent falls in postmenopausal breast cancer survivors and matched cancer-free controls.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22100-e22100.	0.8	0
84	A comprehensive evaluation of breast cancer treatment delays by race among Women's Health Initiative participants.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18579-e18579.	0.8	0
85	Low-fat dietary pattern and all cancer mortality in the Women's Health Initiative (WHI) randomized trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1500-1500.	0.8	0
86	Intentional Weight Loss and Endometrial Cancer Risk. <i>Journal of Clinical Oncology</i> , 2017, 35, 1189-1193.	0.8	80
87	Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 629-635.	0.8	15
88	Prediagnostic Calcium Intake and Lung Cancer Survival: A Pooled Analysis of 12 Cohort Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1060-1070.	1.1	9
89	Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1924-1931.	1.3	9
90	Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	83

#	ARTICLE	IF	CITATIONS
91	Sex Steroid Hormones and Fracture in a Multiethnic Cohort of Women: The Women's Health Initiative Study (WHI). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1538-1547.	1.8	16
92	Effect of depression before breast cancer diagnosis on mortality among postmenopausal women. <i>Cancer</i> , 2017, 123, 3107-3115.	2.0	34
93	Response. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 633-634.	1.1	0
94	Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw215.	3.0	53
95	Sedentary time and postmenopausal breast cancer incidence. <i>Cancer Causes and Control</i> , 2017, 28, 1405-1416.	0.8	10
96	Metabolic Obesity Phenotypes and Risk of Breast Cancer in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1730-1735.	1.1	84
97	Serum 25-hydroxyvitamin D concentrations and lung cancer risk in never-smoking postmenopausal women. <i>Cancer Causes and Control</i> , 2017, 28, 1053-1063.	0.8	6
98	Methodological considerations for disentangling a risk factor's influence on disease incidence versus postdiagnosis survival: The example of obesity and breast and colorectal cancer mortality in the Women's Health Initiative. <i>International Journal of Cancer</i> , 2017, 141, 2281-2290.	2.3	17
99	Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 927.	3.8	407
100	Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial. <i>Menopause</i> , 2017, 24, 133-141.	0.8	16
101	Use of Calcium Channel Blockers and Breast Cancer Risk in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1345-1348.	1.1	15
102	Lifestyle and Breast Cancer. , 2017, , 831-839.		0
103	Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 185-190.	1.1	17
104	Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women. <i>Cancers</i> , 2017, 9, 144.	1.7	23
105	Post-diagnosis body mass index and mortality among women diagnosed with endometrial cancer: Results from the Women's Health Initiative. <i>PLoS ONE</i> , 2017, 12, e0171250.	1.1	8
106	Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 2919-2926.	0.8	104
107	Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women's Health Initiative. <i>PLoS ONE</i> , 2017, 12, e0184174.	1.1	64
108	Intentional weight loss and cancer risk. <i>Oncotarget</i> , 2017, 8, 81719-81720.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative. <i>International Journal of Cancer</i> , 2016, 138, 1915-1927.	2.3	39
110	Pet Ownership and Cancer Risk in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1311-1316.	1.1	10
111	Obesity and Cancer: Insights for Clinicians. <i>Journal of Clinical Oncology</i> , 2016, 34, 4197-4202.	0.8	29
112	Weight Loss Randomized Intervention Trials in Female Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2016, 34, 4238-4248.	0.8	61
113	Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. <i>Journal of Clinical Oncology</i> , 2016, 34, 4249-4255.	0.8	77
114	Alcohol Use and Breast Cancer Survival among Participants in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1268-1273.	1.1	17
115	Cardiovascular Disease After Aromatase Inhibitor Use. <i>JAMA Oncology</i> , 2016, 2, 1590.	3.4	74
116	Association between dietary inflammatory potential and breast cancer incidence and death: results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016, 114, 1277-1285.	2.9	83
117	Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative. <i>International Journal of Cancer</i> , 2016, 139, 2178-2192.	2.3	31
118	Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 547-562.	1.1	8
119	Menopausal estrogen therapy and non-Hodgkin's lymphoma: A post-hoc analysis of women's health initiative randomized clinical trial. <i>International Journal of Cancer</i> , 2016, 138, 604-611.	2.3	13
120	Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 567-576.	1.1	6
121	Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention. <i>New England Journal of Medicine</i> , 2016, 375, 274-275.	13.9	2
122	Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. <i>Journal of Clinical Oncology</i> , 2016, 34, 2899-2905.	0.8	49
123	Statin use and all-cancer survival: prospective results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016, 115, 129-135.	2.9	80
124	Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. <i>Clinical Lung Cancer</i> , 2016, 17, 10-17.e1.	1.1	30
125	Performance of the Breast Cancer Risk Assessment Tool Among Women Age 75 Years and Older. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv348.	3.0	16
126	Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative. <i>Journal of Clinical Oncology</i> , 2016, 34, 360-368.	0.8	29



#	ARTICLE	IF	CITATIONS
127	Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1004-1013.	0.5	44
128	Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 917-924.	2.3	16
129	Estrogen and colorectal cancer incidence and mortality. <i>Cancer</i> , 2015, 121, 3261-3271.	2.0	30
130	Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. <i>Journal of Cancer Epidemiology</i> , 2015, 2015, 1-7.	0.5	3
131	Association Between Obesity and Postmenopausal Breast Cancer Risk—Reply. <i>JAMA Oncology</i> , 2015, 1, 1171.	3.4	0
132	Metformin and breast and gynecological cancer risk among women with diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000049.	1.2	29
133	IBIS-I tamoxifen update: maturity brings questions. <i>Lancet Oncology</i> , The, 2015, 16, 7-9.	5.1	37
134	Risk of breast, endometrial, colorectal, and renal cancers in postmenopausal women in association with a body shape index and other anthropometric measures. <i>Cancer Causes and Control</i> , 2015, 26, 219-229.	0.8	49
135	Statins and breast cancer stage and mortality in the Women's Health Initiative. <i>Cancer Causes and Control</i> , 2015, 26, 529-539.	0.8	52
136	Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1186-1190.	0.8	17
137	Interpreting quality-of-life data from the SOFT and TEXT trials. <i>Lancet Oncology</i> , The, 2015, 16, 749-751.	5.1	6
138	Reliable evidence from placebo-controlled, randomized, clinical trials for menopausal hormone therapy's influence on incidence and deaths from breast cancer. <i>Climacteric</i> , 2015, 18, 336-338.	1.1	4
139	Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk. <i>JAMA Oncology</i> , 2015, 1, 611.	3.4	451
140	Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. <i>Cancer</i> , 2015, 121, 2147-2155.	2.0	43
141	Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone. <i>JAMA Oncology</i> , 2015, 1, 296.	3.4	177
142	Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index: Figure 1.. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv327.	3.0	29
143	Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	83
144	Menopausal hormone therapy and breast cancer mortality: clinical implications. <i>Therapeutic Advances in Drug Safety</i> , 2015, 6, 45-56.	1.0	26

#	ARTICLE	IF	CITATIONS
145	SNPs and breast cancer risk prediction for African American and Hispanic women. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 583-589.	1.1	49
146	Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 609-616.	1.1	18
147	Relationships between dog ownership and physical activity in postmenopausal women. <i>Preventive Medicine</i> , 2015, 70, 33-38.	1.6	44
148	Cardiovascular Toxicity Following Aromatase Inhibitor Use in 13,273 Women Cared for in an HMO. <i>Journal of Patient-centered Research and Reviews</i> , 2015, 2, 88.	0.6	0
149	Reply to P. Niravath et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3780-3781.	0.8	0
150	Dietary Cadmium Exposure and Risk of Breast, Endometrial, and Ovarian Cancer in the Women's Health Initiative. <i>Environmental Health Perspectives</i> , 2014, 122, 594-600.	2.8	91
151	Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer. <i>Clinical Investigation</i> , 2014, 4, 19-33.	0.0	9
152	Walking speed, physical activity, and breast cancer in postmenopausal women. <i>European Journal of Cancer Prevention</i> , 2014, 23, 49-52.	0.6	5
153	Cancer Incidence and Mortality during the Intervention and Postintervention Periods of the Women's Health Initiative Dietary Modification Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2924-2935.	1.1	45
154	Hormone Therapy Use and Outcomes in the Women's Health Initiative Trials—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 417.	3.8	2
155	Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. <i>Obstetrical and Gynecological Survey</i> , 2014, 69, 83-85.	0.2	4
156	Adjuvant Endocrine Therapy of Perimenopausal and Recently Postmenopausal Women With Hormone Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 147-153.	1.1	17
157	Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: Results from the Women's Health Initiative. <i>Gynecologic Oncology</i> , 2014, 133, 4-10.	0.6	59
158	Birth weight and subsequent risk of cancer. <i>Cancer Epidemiology</i> , 2014, 38, 538-543.	0.8	57
159	Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1427-1436.	0.8	49
160	Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings. <i>Cancer Prevention Research</i> , 2014, 7, 378-387.	0.7	147
161	Nutrition and Physical Activity Cancer Prevention Guidelines, Cancer Risk, and Mortality in the Women's Health Initiative. <i>Cancer Prevention Research</i> , 2014, 7, 42-53.	0.7	190
162	Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. <i>Breast Cancer Research</i> , 2014, 16, R30.	2.2	22

#	ARTICLE	IF	CITATIONS
163	Menopausal hormone therapy and cancer: Changing clinical observations of target site specificity. <i>Steroids</i> , 2014, 90, 53-59.	0.8	32
164	Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial. <i>Annals of Internal Medicine</i> , 2014, 160, 594.	2.0	53
165	Current concepts in breast cancer chemoprevention. <i>Polish Archives of Internal Medicine</i> , 2014, 124, 191-199.	0.3	6
166	Racial/ethnic variations in lung cancer incidence and mortality, adjusted for smoking behavior: Results from the Women's Health Initiative.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1528-1528.	0.8	0
167	Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 461-468.	1.1	27
168	Frequency of private spiritual activity and cardiovascular risk in postmenopausal women: the Women's Health Initiative. <i>Annals of Epidemiology</i> , 2013, 23, 239-245.	0.9	16
169	Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1353.	3.8	1,165
170	Calcium Plus Vitamin D Supplementation and Health Outcomes Five Years After Active Intervention Ended: The Women's Health Initiative. <i>Journal of Women's Health</i> , 2013, 22, 915-929.	1.5	98
171	Calcium Plus Vitamin D Supplementation and Joint Symptoms in Postmenopausal Women in the Women's Health Initiative Randomized Trial. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2013, 113, 1302-1310.	0.4	19
172	Investigating the Association of Lactation History and Postmenopausal Breast Cancer Risk in the Women's Health Initiative. <i>Nutrition and Cancer</i> , 2013, 65, 969-981.	0.9	7
173	Sex Hormone Levels and Risk of Breast Cancer With Estrogen Plus Progestin. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1496-1503.	3.0	27
174	Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. <i>Cancer Epidemiology</i> , 2013, 37, 742-749.	0.8	52
175	Nutrition and physical activity influence on breast cancer incidence and outcome. <i>Breast</i> , 2013, 22, S30-S37.	0.9	99
176	Body mass index, physical activity, and survival after endometrial cancer diagnosis: Results from the Women's Health Initiative. <i>Gynecologic Oncology</i> , 2013, 128, 181-186.	0.6	48
177	Changing Concepts of Hormone Receptor-Positive Advanced Breast Cancer Therapy. <i>Clinical Breast Cancer</i> , 2013, 13, 159-166.	1.1	24
178	Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women. <i>Cancer Causes and Control</i> , 2013, 24, 577-585.	0.8	22
179	Prospective Analysis of Association between Statin Use and Breast Cancer Risk in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1868-1876.	1.1	41
180	Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings. <i>Journal of Family Planning and Reproductive Health Care</i> , 2013, 39, 226-228.	0.9	0

#	ARTICLE	IF	CITATIONS
181	Racial/Ethnic Differences in Use and Duration of Adjuvant Hormonal Therapy for Breast Cancer in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 365-373.	1.1	23
182	Regression Calibration in Nutritional Epidemiology: Example of Fat Density and Total Energy in Relationship to Postmenopausal Breast Cancer. <i>American Journal of Epidemiology</i> , 2013, 178, 1663-1672.	1.6	29
183	Severity of comorbid conditions and early-stage breast cancer therapy: linked SEER Medicare data from 1993 to 2005. <i>Cancer Medicine</i> , 2013, 2, 526-536.	1.3	8
184	Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2043-2048.	3.1	15
185	Adjuvant Aromatase Inhibitor Options in Overweight and Obese Postmenopausal Women with Breast Cancer. <i>Breast Journal</i> , 2013, 19, n/a-n/a.	0.4	2
186	Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women's Health Initiative Observational Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 526-535.	3.0	165
187	Reply to S. Gandini et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 974-975.	0.8	2
188	Vitamin D intake and lung cancer risk in the Women's Health Initiative. <i>American Journal of Clinical Nutrition</i> , 2013, 98, 1002-1011.	2.2	44
189	Association between Sleep and Breast Cancer Incidence among Postmenopausal Women in the Women's Health Initiative. <i>Sleep</i> , 2013, 36, 1437-1444.	0.6	66
190	Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. <i>Menopause</i> , 2013, 20, 600-608.	0.8	49
191	Diabetes, Metformin, and Breast Cancer in Postmenopausal Women. <i>Journal of Clinical Oncology</i> , 2012, 30, 2844-2852.	0.8	179
192	Diabetes and Lung Cancer Among Postmenopausal Women. <i>Diabetes Care</i> , 2012, 35, 1485-1491.	4.3	35
193	Changing Concepts: Menopausal Hormone Therapy and Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 517-527.	3.0	125
194	Vitamin D and Calcium Supplementation and One-Year Change in Mammographic Density in the Women's Health Initiative Calcium and Vitamin D Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 462-473.	1.1	24
195	Quantifying Mediating Effects of Endogenous Estrogen and Insulin in the Relation between Obesity, Alcohol Consumption, and Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1203-1212.	1.1	55
196	Estrogen Plus Progestin and Colorectal Cancer Incidence and Mortality. <i>Journal of Clinical Oncology</i> , 2012, 30, 3983-3990.	0.8	95
197	Adipokines Linking Obesity with Colorectal Cancer Risk in Postmenopausal Women. <i>Cancer Research</i> , 2012, 72, 3029-3037.	0.4	135
198	Hormone Therapy, Estrogen Metabolism, and Risk of Breast Cancer in the Women's Health Initiative Hormone Therapy Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 2022-2032.	1.1	10

#	ARTICLE	IF	CITATIONS
199	Caution in reinterpreting the Women's Health Initiative (WHI) Calcium and Vitamin D Trial breast cancer results. <i>American Journal of Clinical Nutrition</i> , 2012, 95, 258-259.	2.2	10
200	Bisphosphonates and Breast Cancer Prevention. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 144-150.	0.9	17
201	Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. <i>Lancet Oncology</i> , 2012, 13, 476-486.	5.1	314
202	Metformin and breast cancer risk: a meta-analysis and critical literature review. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 639-646.	1.1	183
203	Recreational physical activity, body mass index, and survival in women with colorectal cancer. <i>Cancer Causes and Control</i> , 2012, 23, 1939-1948.	0.8	101
204	Postmenopausal Women with DCIS Post-Mastectomy: A Potential Role for Aromatase Inhibitors. <i>Breast Journal</i> , 2012, 18, 299-302.	0.4	1
205	Clinical Perspective: Influence of Modifiable Lifestyle Factors, Body Weight, Physical Activity, and Alcohol on Breast Cancer Outcome. <i>Current Breast Cancer Reports</i> , 2012, 4, 188-198.	0.5	0
206	Birth Weight, Breast Cancer and the Potential Mediating Hormonal Environment. <i>PLoS ONE</i> , 2012, 7, e40199.	1.1	39
207	Social networks, social support and burden in relationships, and mortality after breast cancer diagnosis. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 375-385.	1.1	51
208	Hematopoietic prostaglandin D synthase (HPGDS): A high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer. <i>Prostaglandins and Other Lipid Mediators</i> , 2012, 97, 22-28.	1.0	11
209	Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 969-979.	1.1	23
210	Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 275-285.	1.1	52
211	Fine mapping of 14q24.1 breast cancer susceptibility locus. <i>Human Genetics</i> , 2012, 131, 479-490.	1.8	5
212	Diabetes, metformin use, and colorectal cancer survival in women: A retrospective cohort study. <i>Journal of Clinical Oncology</i> , 2012, 30, e14005-e14005.	0.8	4
213	Hormonal Factors and Risks of Esophageal Squamous Cell Carcinoma and Adenocarcinoma in Postmenopausal Women. <i>Cancer Prevention Research</i> , 2011, 4, 840-850.	0.7	50
214	Dietary Glycemic Load, Glycemic Index, and Carbohydrate and Risk of Breast Cancer in the Women's Health Initiative. <i>Nutrition and Cancer</i> , 2011, 63, 899-907.	0.9	51
215	The Effect of Calcium plus Vitamin D on Risk for Invasive Cancer: Results of the Women's Health Initiative (WHI) Calcium Plus Vitamin D Randomized Clinical Trial. <i>Nutrition and Cancer</i> , 2011, 63, 827-841.	0.9	76
216	Exemestane for Breast-Cancer Prevention in Postmenopausal Women. <i>New England Journal of Medicine</i> , 2011, 364, 2381-2391.	13.9	847

#	ARTICLE	IF	CITATIONS
217	25-Hydroxyvitamin D concentration, vitamin D intake and joint symptoms in postmenopausal women. <i>Maturitas</i> , 2011, 68, 73-78.	1.0	28
218	Vitamin D and breast cancer: interpreting current evidence. <i>Breast Cancer Research</i> , 2011, 13, 217.	2.2	47
219	Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 470-477.	3.0	190
220	Placebo Adherence, Clinical Outcomes, and Mortality in the Women's Health Initiative Randomized Hormone Therapy Trials. <i>Medical Care</i> , 2011, 49, 427-435.	1.1	55
221	Interaction Between Body Mass Index and Central Adiposity and Risk of Incident Cognitive Impairment and Dementia: Results from the Women's Health Initiative Memory Study. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 107-112.	1.3	80
222	Cost-Effectiveness Analysis of a Low-Fat Diet in the Prevention of Breast and Ovarian Cancer. <i>Journal of the American Dietetic Association</i> , 2011, 111, 56-66.	1.3	15
223	Reproductive and menstrual factors and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. <i>Cancer Causes and Control</i> , 2011, 22, 1415-1424.	0.8	18
224	Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis. <i>Cancer</i> , 2011, 117, 3252-3261.	2.0	50
225	Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1305.	3.8	483
226	Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor-Positive Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 454-463.	1.1	160
227	Racial Differences in Colorectal Cancer Incidence and Mortality in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1368-1378.	1.1	27
228	Menopausal Hormone Therapy and Risks of Melanoma and Nonmelanoma Skin Cancers: Women's Health Initiative Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1469-1475.	3.0	58
229	Physical Activity and Survival in Postmenopausal Women with Breast Cancer: Results from the Women's Health Initiative. <i>Cancer Prevention Research</i> , 2011, 4, 522-529.	0.7	238
230	Breast Cancer in Postmenopausal Women After Hormone Therapy—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 466.	3.8	0
231	Sex Hormone Levels and Risks of Estrogen Receptor-Negative and Estrogen Receptor-Positive Breast Cancers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 562-570.	3.0	88
232	The Influence of Time From Menopause and Mammography on Hormone Therapy-Related Breast Cancer Risk Assessment. <i>Journal of the National Cancer Institute</i> , 2011, 103, 284-285.	3.0	15
233	Dietary vitamin D and calcium intake and mammographic density in postmenopausal women. <i>Menopause</i> , 2010, 17, 1152-1160.	0.8	18
234	Hormone Therapy Suspension and Mammography in Women's Health Initiative Clinical Trials. <i>Annals of Internal Medicine</i> , 2010, 152, 133.	2.0	0

#	ARTICLE	IF	CITATIONS
235	Recreational physical activity, anthropometric factors, and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. <i>Cancer Causes and Control</i> , 2010, 21, 2173-2181.	0.8	10
236	Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women. <i>Journal of Clinical Oncology</i> , 2010, 28, 3582-3590.	0.8	182
237	Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1413-1421.	3.0	100
238	Prospective evaluation of two recruitment strategies for a randomized controlled cancer prevention trial. <i>Clinical Trials</i> , 2010, 7, 744-748.	0.7	10
239	Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1684.	3.8	457
240	Alcohol Consumption and Risk of Ductal Carcinoma <i>in situ</i> of the Breast in a Cohort of Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2066-2072.	1.1	15
241	Alcohol Consumption and Risk of Postmenopausal Breast Cancer by Subtype: The Women's Health Initiative Observational Study. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1422-1431.	3.0	121
242	Estrogen Alone in Postmenopausal Women and Breast Cancer Detection by Means of Mammography and Breast Biopsy. <i>Journal of Clinical Oncology</i> , 2010, 28, 2690-2697.	0.8	39
243	Variation in the <i>FGFR2</i> Gene and the Effect of a Low-Fat Dietary Pattern on Invasive Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 74-79.	1.1	18
244	Bisphosphonates for breast cancer therapy and prevention?. <i>IBMS BoneKEy</i> , 2010, 7, 364-368.	0.1	0
245	Lung cancer and hormone replacement therapy – Authors' reply. <i>Lancet, The</i> , 2010, 375, 118-119.	6.3	1
246	Performance of Common Genetic Variants in Breast-Cancer Risk Models. <i>New England Journal of Medicine</i> , 2010, 362, 986-993.	13.9	376
247	New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk. <i>Archives of Internal Medicine</i> , 2009, 169, 1684.	4.3	19
248	American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. <i>Journal of Clinical Oncology</i> , 2009, 27, 3235-3258.	0.8	254
249	Aromatase Inhibitor-Associated Arthralgias. <i>Journal of Clinical Oncology</i> , 2009, 27, 4932-4934.	0.8	35
250	Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women. <i>New England Journal of Medicine</i> , 2009, 360, 573-587.	13.9	412
251	Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women. <i>American Journal of Clinical Nutrition</i> , 2009, 90, 162-169.	2.2	76
252	Conjugated Equine Estrogen Influence on Mammographic Density in Postmenopausal Women in a Substudy of the Women's Health Initiative Randomized Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 6135-6143.	0.8	58

#	ARTICLE	IF	CITATIONS
253	Variation in the <i>FGFR2</i> Gene and the Effects of Postmenopausal Hormone Therapy on Invasive Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 3079-3085.	1.1	54
254	American Society of Clinical Oncology Policy Statement: The Role of the Oncologist in Cancer Prevention and Risk Assessment. <i>Journal of Clinical Oncology</i> , 2009, 27, 986-993.	0.8	55
255	Caution Regarding 25-Hydroxyvitamin D Monitoring in Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, e72-e73.	0.8	5
256	Sexual Dysfunction and Aromatase Inhibitor Use in Survivors of Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, 219-224.	1.1	24
257	Implementing a Low-Fat Eating Plan in the Women's Intervention Nutrition Study. <i>Journal of the American Dietetic Association</i> , 2009, 109, 688-696.	1.3	50
258	Menopausal Hormone Therapy, Hormone Receptor Status, and Lung Cancer in Women. <i>Seminars in Oncology</i> , 2009, 36, 566-571.	0.8	22
259	Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. <i>Breast</i> , 2009, 18, S1-S11.	0.9	35
260	Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. <i>International Journal of Cancer</i> , 2009, 125, 2704-2710.	2.3	134
261	A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 339-350.	1.1	29
262	Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 81-87.	1.1	93
263	A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). <i>Nature Genetics</i> , 2009, 41, 579-584.	9.4	487
264	Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative) <i>Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50</i>	6.3	282
265	Influence of stressors on breast cancer incidence in the Women's Health Initiative.. <i>Health Psychology</i> , 2009, 28, 137-146.	1.3	79
266	Early breast and prostate cancer and clinical outcomes (fracture). <i>Oncology</i> , 2009, 23, 16-20.	0.4	4
267	Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 25-34.	1.1	33
268	Hip bone density predicts breast cancer risk independently of Gail score. <i>Cancer</i> , 2008, 113, 907-915.	2.0	74
269	Clinical Trial Presentations, Agency Guidelines, and Oncology Practice: Findings from the Arimidex, Tamoxifen, Alone or in Combination Trial. <i>Clinical Breast Cancer</i> , 2008, 8, 343-346.	1.1	4
270	Calcium Plus Vitamin D Supplementation and the Risk of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1581-1591.	3.0	384



#	ARTICLE	IF	CITATIONS
271	Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. JAMA - Journal of the American Medical Association, 2008, 299, 1036.	3.8	344
272	Menopausal Hormone Therapy in BRCA1 Mutation Carriers: Uncertainty and Caution. Journal of the National Cancer Institute, 2008, 100, 1341-1343.	3.0	14
273	Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer. Journal of Clinical Oncology, 2008, 26, 4875-4882.	0.8	444
274	Estrogen plus Progestin and Risk of Benign Proliferative Breast Disease. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2337-2343.	1.1	35
275	Adherence to Oral Endocrine Therapy for Breast Cancer: A Nursing Perspective. Clinical Journal of Oncology Nursing, 2008, 12, 213-221.	0.3	52
276	Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women. American Journal of Epidemiology, 2008, 167, 1207-1216.	1.6	126
277	Estrogen Plus Progestin and Breast Cancer Detection by Means of Mammography and Breast Biopsy. Archives of Internal Medicine, 2008, 168, 370.	4.3	82
278	Body Mass Index and Waist Circumference in Relation to Lung Cancer Risk in the Women's Health Initiative. American Journal of Epidemiology, 2008, 168, 158-169.	1.6	85
279	Conjugated Equine Estrogen and Risk of Benign Proliferative Breast Disease: A Randomized Controlled Trial. Journal of the National Cancer Institute, 2008, 100, 563-571.	3.0	49
280	Low-Fat Dietary Pattern and Risk of Benign Proliferative Breast Disease: A Randomized, Controlled Dietary Modification Trial. Cancer Prevention Research, 2008, 1, 275-284.	0.7	14
281	Conjugated Equine Estrogens and Breast Cancer Risk in the Women's Health Initiative Clinical Trial and Observational Study. American Journal of Epidemiology, 2008, 167, 1407-1415.	1.6	126
282	Conjugated Equine Estrogens and Colorectal Cancer Incidence and Survival: The Women's Health Initiative Randomized Clinical Trial. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2609-2618.	1.1	87
283	Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk. Menopause, 2008, 15, 804-809.	0.8	5
284	Colorectal Cancer in Women After Stopping Postmenopausal Hormone Therapy—Reply. JAMA - Journal of the American Medical Association, 2008, 299, 2744.	3.8	0
285	Low-Fat Dietary Pattern and Cancer Incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. Journal of the National Cancer Institute, 2007, 99, 1534-1543.	3.0	194
286	The Decrease in Breast-Cancer Incidence in 2003 in the United States. New England Journal of Medicine, 2007, 356, 1670-1674.	13.9	879
287	Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status. Journal of the National Cancer Institute, 2007, 99, 1695-1705.	3.0	117
288	Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocrine-Related Cancer, 2007, 14, 169-187.	1.6	165

#	ARTICLE	IF	CITATIONS
289	Lifestyle Change Including Dietary Fat Reduction and Breast Cancer Outcome. <i>Journal of Nutrition</i> , 2007, 137, 233S-235S.	1.3	18
290	Alcohol and folate consumption and risk of benign proliferative epithelial disorders of the breast. <i>International Journal of Cancer</i> , 2007, 121, 1346-1351.	2.3	20
291	National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: Evaluation of Exemestane to Prevent Breast Cancer in Postmenopausal Women. <i>Clinical Breast Cancer</i> , 2007, 7, 895-900.	1.1	19
292	Cigarette smoking and risk of benign proliferative epithelial disorders of the breast in the Women's Health Initiative. <i>Cancer Causes and Control</i> , 2007, 18, 431-438.	0.8	12
293	Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer. <i>New England Journal of Medicine</i> , 2006, 354, 684-696.	13.9	907
294	Calcium plus Vitamin D Supplementation and the Risk of Fractures. <i>New England Journal of Medicine</i> , 2006, 354, 669-683.	13.9	1,674
295	Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. <i>Maturitas</i> , 2006, 55, 103-115.	1.0	214
296	Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. <i>International Journal of Cancer</i> , 2006, 118, 1292-1301.	2.3	35
297	Adherence to Endocrine Therapy for Breast Cancer. <i>Oncology</i> , 2006, 71, 1-9.	0.9	276
298	Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. <i>Current Medical Research and Opinion</i> , 2006, 22, 1575-1585.	0.9	30
299	Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative. <i>Journal of the National Cancer Institute</i> , 2006, 98, 700-707.	3.0	169
300	Low-Fat Dietary Pattern and Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 655.	3.8	939
301	Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1647.	3.8	497
302	Low-Fat Dietary Pattern and Risk of Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 643.	3.8	355
303	Low-Fat Dietary Pattern and Risk of Invasive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 629.	3.8	696
304	Low-Fat Diet and Risk of Breast Cancer—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 278.	3.8	3
305	The Association between Aspirin Use and the Incidence of Colorectal Cancer in Women. <i>American Journal of Epidemiology</i> , 2006, 164, 567-575.	1.6	30
306	Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1767-1776.	3.0	745

#	ARTICLE	IF	CITATIONS
307	Abnormal Mammographic Findings with Short-Interval Follow-up Recommendation. <i>Clinical Breast Cancer</i> , 2005, 6, 235-239.	1.1	5
308	Progestins and Recurrence in Breast Cancer Survivors. <i>Journal of the National Cancer Institute</i> , 2005, 97, 471-472.	3.0	11
309	Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1366-1376.	3.0	240
310	Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome. <i>Journal of the National Cancer Institute</i> , 2005, 97, 439-448.	3.0	539
311	RESPONSE: Re: Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1619-1620.	3.0	5
312	Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 1701.	3.8	3,881
313	Insulin, Physical Activity, and Caloric Intake in Postmenopausal Women: Breast Cancer Implications. <i>Journal of Clinical Oncology</i> , 2004, 22, 4507-4513.	0.8	45
314	Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women. <i>New England Journal of Medicine</i> , 2004, 350, 991-1004.	13.9	585
315	Menopausal hormone therapy after breast cancer. <i>Lancet, The</i> , 2004, 363, 410-411.	6.3	24
316	Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. <i>Seminars in Oncology</i> , 2003, 30, 776-788.	0.8	25
317	The American Cancer Society Guide for Nutrition and Physical Activity for Cancer Survivors: A Call to Action for Clinical Investigators. <i>Ca-A Cancer Journal for Clinicians</i> , 2003, 53, 266-267.	157.7	9
318	Research staff turnover and participant adherence in the Women's Health Initiative. <i>Contemporary Clinical Trials</i> , 2003, 24, 422-435.	2.0	15
319	Meta-analysis of vascular and neoplastic events associated with tamoxifen. <i>Journal of General Internal Medicine</i> , 2003, 18, 937-947.	1.3	326
320	HT and breast cancer risk. <i>Sexuality, Reproduction &amp; Menopause</i> , 2003, 1, 15-18.	1.0	2
321	The women's health initiative dietary modification trial: overview and baseline characteristics of participants. <i>Annals of Epidemiology</i> , 2003, 13, S87-S97.	0.9	185
322	Differences between estimated caloric requirements and self-reported caloric intake in the women's health initiative. <i>Annals of Epidemiology</i> , 2003, 13, 629-637.	0.9	48
323	American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 4042-4057.	0.8	915
324	Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 3243.	3.8	1,603

#	ARTICLE	IF	CITATIONS
325	Biological Significance of Interventions That Change Breast Density. Journal of the National Cancer Institute, 2003, 95, 4-5.	3.0	34
326	Frequency and Predictive Value of a Mammographic Recommendation for Short-Interval Follow-Up. Journal of the National Cancer Institute, 2003, 95, 429-436.	3.0	84
327	American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting. Journal of Clinical Oncology, 2003, 21, 2597-2599.	0.8	81
328	Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Research, 2003, 63, 6096-101.	0.4	277
329	American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition. Journal of Clinical Oncology, 2002, 20, 3328-3343.	0.8	187
330	The Effects of Tamoxifen and Estrogen on Brain Metabolism in Elderly Women. Journal of the National Cancer Institute, 2002, 94, 592-597.	3.0	100
331	American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002. Journal of Clinical Oncology, 2002, 20, 3317-3327.	0.8	213
332	Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model. Medical Decision Making, 2002, 22, 386-393.	1.2	8
333	Breast Cancer Risk Reduction: Strategies for Women at Increased Risk. Annual Review of Medicine, 2002, 53, 519-540.	5.0	31
334	Weight Loss in Breast Cancer Patient Management. Journal of Clinical Oncology, 2002, 20, 1128-1143.	0.8	535
335	Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United) Tj ETQq1 1 0,784314 rrgBT /Ov	0.8	472
336	Trends in Prostate and Breast Cancer Clinical Research as Reported in the American Society of Clinical Oncology Proceedings. Prostate Journal, 2001, 3, 26-29.	0.2	0
337	Factors influencing the role of bisphosphonates in breast cancer management. Seminars in Oncology, 2001, 28, 42-48.	0.8	1
338	American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer. Journal of Clinical Oncology, 2000, 18, 1378-1391.	0.8	355
339	Reducing the Risk of Breast Cancer. New England Journal of Medicine, 2000, 343, 191-198.	13.9	61
340	Tamoxifen for Treatment of Premenopausal Women with Breast Cancer. Cancer Investigation, 2000, 18, 681-684.	0.6	0
341	Elements of Informed Consent for Hormone Replacement Therapy in Patients With Diagnosed Breast Cancer. Journal of Clinical Oncology, 1999, 17, 130-130.	0.8	39
342	American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene. Journal of Clinical Oncology, 1999, 17, 1939-1939.	0.8	160

#	ARTICLE	IF	CITATIONS
343	Monitoring Dietary Change in a Low-Fat Diet Intervention Study. <i>Journal of the American Dietetic Association</i> , 1996, 96, 574-579.	1.3	148
344	Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. , 1996, 78, 2119-2126.		56
345	Altered Metabolism and Mortality in Patients With Colon Cancer Receiving Chemotherapy. <i>American Journal of the Medical Sciences</i> , 1995, 310, 48-55.	0.4	9
346	Dietary Intake and Counseling, Weight Maintenance, and the Course of HIV Infection. <i>Journal of the American Dietetic Association</i> , 1995, 95, 428-435.	1.3	71
347	5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma. <i>Investigational New Drugs</i> , 1994, 12, 57-63.	1.2	22
348	The scope of nutrition intervention trials with cancer-related endpoints. <i>Cancer</i> , 1994, 74, 2734-2738.	2.0	30
349	Breast cancer chemoprevention tamoxifen: Current issues and future prospective. <i>Cancer</i> , 1993, 72, 1032-1037.	2.0	34
350	The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1993, 27, 253-262.	1.1	86
351	New directions in the nutritional management of the cancer patient. <i>Nutrition Research</i> , 1993, 13, 3-21.	1.3	16
352	Metabolic Response to Chemotherapy in Colon Cancer Patients. <i>Journal of Parenteral and Enteral Nutrition</i> , 1992, 16, 65S-71S.	1.3	12
353	Unpublished data summaries and the design and conduct of clinical trials. <i>Contemporary Clinical Trials</i> , 1989, 10, 368-377.	2.0	8
354	Mitoxantrone use in breast cancer patients with elevated bilirubin. <i>Breast Cancer Research and Treatment</i> , 1989, 14, 267-274.	1.1	5
355	Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. <i>Cancer</i> , 1989, 63, 330-334.	2.0	164
356	A breast cancer nutrition adjuvant study (NAS): Protocol design and initial patient adherence. <i>Breast Cancer Research and Treatment</i> , 1987, 10, 21-29.	1.1	37
357	Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. <i>Cancer</i> , 1987, 59, 406-410.	2.0	65
358	Metabolic Abnormalities in Cancer Patients: Carbohydrate Metabolism. <i>Surgical Clinics of North America</i> , 1986, 66, 957-968.	0.5	43
359	Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. <i>Cancer</i> , 1986, 58, 183-186.	2.0	89
360	Pathophysiology of malnutrition in the adult cancer patient. <i>Cancer</i> , 1986, 58, 1867-1873.	2.0	82

#	ARTICLE	IF	CITATIONS
361	Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy. <i>Breast Cancer Research and Treatment</i> , 1986, 7, 23-30.	1.1	122
362	Pathophysiology of malnutrition in the adult cancer patient. <i>Cancer</i> , 1986, 58, 1867-1873.	2.0	46
363	Doxorubicin, cyclophosphamide, CCNU, and vincristine with or without cisplatin in non-small cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1985, 8, 157-161.	0.6	1
364	Metabolic abnormalities in the cancer patient. <i>Cancer</i> , 1985, 55, 225-229.	2.0	94
365	Critical evaluation of the role of nutritional support with chemotherapy. <i>Cancer</i> , 1985, 55, 268-272.	2.0	37
366	Influence of nutritional status on circulatory ribonuclease C levels in patients with cancer. <i>Cancer</i> , 1985, 55, 427-431.	2.0	2
367	Significance of altered nutritional status in acquired immune deficiency syndrome (AIDS). <i>Nutrition and Cancer</i> , 1985, 7, 85-91.	0.9	77
368	Vitamin K in the treatment of cancer. <i>Cancer Treatment Reviews</i> , 1985, 12, 49-63.	3.4	50
369	Differential pulse polarographic determination of plasma menadione. <i>Analytical Biochemistry</i> , 1984, 141, 488-493.	1.1	24
370	Hepatocellular carcinoma diagnostic and prognostic features in north american patients. <i>Cancer</i> , 1984, 53, 2701-2706.	2.0	151
371	Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer a randomized trial. <i>Cancer</i> , 1983, 52, 606-609.	2.0	6
372	Dosimetry and preliminary human studies of 18F-5-fluorouracil. <i>International Journal of Nuclear Medicine and Biology</i> , 1982, 9, 25-35.	0.7	29
373	Factors influencing the interim interpretation of a breast cancer trial: Danger of achieving the "expected" result. <i>Contemporary Clinical Trials</i> , 1981, 2, 123-132.	2.0	7
374	Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: Clinical and pharmacokinetic aspects. <i>Cancer</i> , 1981, 48, 1088-1095.	2.0	36
375	Treatment of advanced breast carcinoma with 5-fluorouracil: A randomized comparison of two routes of delivery. <i>Cancer</i> , 1981, 48, 1711-1714.	2.0	15
376	Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil. Prognostic aspects of the differential white blood cell count. <i>Cancer</i> , 1980, 45, 2240-2244.	2.0	19
377	Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC Tj ETQq1 1 0.784314 rgB / Cancer, 1978, 42, 2546-2552.	2.0	49